转化医学杂志
轉化醫學雜誌
전화의학잡지
Translational Medicine Journal
2015年
5期
282-284
,共3页
阿托伐他汀钙片%慢性阻塞性肺疾病%生活质量
阿託伐他汀鈣片%慢性阻塞性肺疾病%生活質量
아탁벌타정개편%만성조새성폐질병%생활질량
Atorvastatin calcium tablets%Chronic obstructive pulmonary disease (COPD)%Quality of life
目的：观察应用阿托伐他汀钙片对稳定期慢性阻塞性肺疾病（ chronic obstructive pulmonary di－sease，COPD）患者血清C反应蛋白（C－reactive protein，CRP）、白介素－6（interleukin－6，IL－6）和肺功能的影响。方法将60例稳定期COPD患者随机分成2组（干预组和对照组各30例），2组均给予常规治疗，干预组在常规治疗基础上加服阿托伐他汀钙片，经1年治疗后观察2组治疗前、后血清CRP I、L－6水平及COPD评估测试（ COPD assessment test，CAT）评分和肺功能，连续追踪2年。结果治疗前2组血清CRP、 IL－6水平及CAT评分和生活质量评分差异均无统计学意义（P＞0．05）。治疗后干预组血清CRP、IL－6水平均低于对照组（P＜0．05），而CAT评分和肺功能明显优于对照组（P＜0．05）。结论阿托伐他汀钙片能降低稳定期COPD患者血清CRP、IL－6，改善患者的生活质量。
目的：觀察應用阿託伐他汀鈣片對穩定期慢性阻塞性肺疾病（ chronic obstructive pulmonary di－sease，COPD）患者血清C反應蛋白（C－reactive protein，CRP）、白介素－6（interleukin－6，IL－6）和肺功能的影響。方法將60例穩定期COPD患者隨機分成2組（榦預組和對照組各30例），2組均給予常規治療，榦預組在常規治療基礎上加服阿託伐他汀鈣片，經1年治療後觀察2組治療前、後血清CRP I、L－6水平及COPD評估測試（ COPD assessment test，CAT）評分和肺功能，連續追蹤2年。結果治療前2組血清CRP、 IL－6水平及CAT評分和生活質量評分差異均無統計學意義（P＞0．05）。治療後榦預組血清CRP、IL－6水平均低于對照組（P＜0．05），而CAT評分和肺功能明顯優于對照組（P＜0．05）。結論阿託伐他汀鈣片能降低穩定期COPD患者血清CRP、IL－6，改善患者的生活質量。
목적：관찰응용아탁벌타정개편대은정기만성조새성폐질병（ chronic obstructive pulmonary di－sease，COPD）환자혈청C반응단백（C－reactive protein，CRP）、백개소－6（interleukin－6，IL－6）화폐공능적영향。방법장60례은정기COPD환자수궤분성2조（간예조화대조조각30례），2조균급여상규치료，간예조재상규치료기출상가복아탁벌타정개편，경1년치료후관찰2조치료전、후혈청CRP I、L－6수평급COPD평고측시（ COPD assessment test，CAT）평분화폐공능，련속추종2년。결과치료전2조혈청CRP、 IL－6수평급CAT평분화생활질량평분차이균무통계학의의（P＞0．05）。치료후간예조혈청CRP、IL－6수평균저우대조조（P＜0．05），이CAT평분화폐공능명현우우대조조（P＜0．05）。결론아탁벌타정개편능강저은정기COPD환자혈청CRP、IL－6，개선환자적생활질량。
Objective To observe the effect of atorvastatin calcium tablets on C-reactive pro-tein( CRP ) , IL-6 and pulmonary function in chronic obstructive pulmonary disease patients of sta-tionary phase.Methods Sixty patients in stationary phase of chronic obstructive pulmonary disease ( COPD) were randomly divided into treatment group and control group.Patients in the control group ( n=30) were treated with conventional therapy, and those in the treatment group were given oral atorvastatin calcium tablets 20 mg on the basis of routine treatment, once per night.The course of treatment was 1 year.The levels of CRP, interleukin ( IL)-6 and the CAT scores and pulmonary function were measured before and after treatment, continuously followed for 2 years.Results The difference in the levels of of CRP , IL-6 and the CAT scores between the two group before treatment were not statistically significant (P>0.05).After 1 year of treatment, levels of CRP, IL-6 in the treatment group were significantly lower than those in the control group ( P<0.05) .CAT scores of the treatment group was significantly better than the control group ( P<0.05 ) .Conclusion Ator-vastatin calcium tablets can reduce levels of CRP, IL-6 in COPD patients of stationary phase and improve the quality of life.
